Explore Drug Addiction Treatment Centers Promising Data on GLP-1s for Addiction A 2024 review identified two randomized control trials that showed a significant effect of GLP-1RA on decreasing SUD. The details: One study pertained to alcohol, the other to nicotine In the alcohol study, participants drank 29% less compared to their baseline intake (Probst et al., 2023) dulaglutide once a week for 12 weeks A third study only showed SUD results (alcohol) for patients who were also obese (Klausen et al., 2022) In this study, one GLP-1 (Exenatide) decreased total intake and the number of heavy drinking days by almost 24% once a week for 26 weeks The 2024 review concludes that GLP-1s have a a potential role in SUD
After youve withdrawn the syringe, use your thumb and forefinger to keep the skin around the injection site taut
Our team reviews health history to confirm compatibility
Can support immune health
Your journey deserves patience, compassion, and tools that truly support you
Taken once a week through a subcutaneous injection, Zepbound targets GLP-1 and GIP receptors for effective weight loss management